HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

AI Briefing

• – TAZVERIK product withdrawal and recall initiated in China, all active clinical trials discontinued, patients advised to consult treating physicians.
• – HUTCHMED limits tazemetostat clinical trials and discontinues them due to Ipsen's US market withdrawal.
• – TAZVERIK therapy no longer available in the US market.